UNMC TEAM MOVES CLOSER TO PARKINSON'S DISEASE VACCINE
UNMC researchers have taken a significant step forward in the development of a vaccine to reverse the neurological damage caused by Parkinson's disease.
The findings appear in the March 1 issue of the Journal of Immunology.
"This could be a revolutionary means for Parkinson's disease therapeutics," said Howard Gendelman, M.D., chairman of the department of pharmacology and experimental neuroscience (PEN), who partnered with R. Lee Mosley, Ph.D., to lead the research. "It has been a long journey representing more than 10 years of hard work by our research team."
The cause of Parkinson's disease -- which affects more than 4 million people worldwide -- is the loss of neurons that produce dopamine, a nerve signaling chemical that controls movement and balance.
Neurodegeneration occurs when a normal protein called alpha synuclein clumps, changes shape, then accumulates in the brain. This results in the body attacking it through inflammation and causing destruction of dopamine-producing nerve cells.
UNMC researchers reversed the neurodegenerative effects of alpha synuclein by changing immune responses to it.
In mice with an experimental form of Parkinson's disease, researchers found that the vaccine enabled T cells to migrate to the damaged area of the brain and triggered a neuroprotective response that reduced disease-linked reactions in the brain.
T cells are white blood cells that are key to immune response. They act like soldiers who search out and destroy the targeted invaders.
Additional work is needed to determine how to safely translate the study results into a therapy for humans, Dr. Gendelman said.
- Interested in Research at UNMC?
- Areas of Emphasis
- Find an Expert
Make a gift
The Nebraska Biobank
Department of Defense Related Research
- Resources for Researchers